Inhibitor Therapeutics signs exclusive worldwide license with JHU for itraconazole in three cancers

Inhibitor Therapeutics, Inc.

Exclusive worldwide license to U.S. Patent 8,980,930 covering itraconazole as an angiogenesis inhibitor.
Licensed field of use: prostate cancer, basal cell carcinoma (including BCC nevus syndrome), and lung cancer.
Financial terms include upfront fee, minimum annual royalties, milestone payments, and royalties on net sales.
Company cites this as a critical milestone toward commercializing itraconazole in multiple oncology indications.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.97

Inhibitor Therapeutics, Inc. entered into Exclusive License Agreement with Johns Hopkins University valued at License agreement including upfront license fee, minimum annual royalty payments, royalties on net s (effective 2023-12-12).

Action: entry
Agreement: license
Counterparty: Johns Hopkins University
Value: License agreement including upfront license fee, minimum annual royalty payments, royalties on net s
Effective: 2023-12-12

Exact text from the filing

On December 12, 2023, Inhibitor Therapeutics, Inc. (the “Company”) entered into an Exclusive License Agreement (the “Agreement”) with Johns Hopkins University (“JHU”).

View on SEC.gov

Browse all material agreements →

Inhibitor Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-294696

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.